ClinicalTrials.gov
ClinicalTrials.gov Menu

Neurobiology of Opioid Dependence: 1 - 1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00000192
Recruitment Status : Withdrawn
First Posted : September 21, 1999
Last Update Posted : August 7, 2015
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Yale University

Brief Summary:
The purpose of this study is to evaluate the effects of lamotrigine on naloxone-precipitated opiate withdrawal.

Condition or disease Intervention/treatment Phase
Opioid-Related Disorders Drug: Lamotrigine Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Masking: Double
Primary Purpose: Treatment
Official Title: Neurobiology of Opioid Dependence: 1
Study Start Date : January 1993
Actual Primary Completion Date : January 1998
Actual Study Completion Date : January 1998

Resource links provided by the National Library of Medicine

Drug Information available for: Lamotrigine




Primary Outcome Measures :
  1. Behavioral, subjective, measures of naloxone-precipitated opiate withdrawal
  2. Phsyiological, neuroendocrine measures of naloxone-precipitated opiate withdrawal


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000192


Locations
United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Marc I Rosen, M.D. VA Connecticut Healthcare System

Publications:
Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT00000192     History of Changes
Other Study ID Numbers: NIDA-00191-1
K20DA000191 ( U.S. NIH Grant/Contract )
K20-00191-1
First Posted: September 21, 1999    Key Record Dates
Last Update Posted: August 7, 2015
Last Verified: August 2015

Keywords provided by Yale University:
opioid disorders

Additional relevant MeSH terms:
Opioid-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Analgesics, Opioid
Lamotrigine
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Anticonvulsants
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers